DISEASE INDICATIONS: Hypercholesterolemia
MANUFACTURER: Novartis
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Kerendia (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney failure, cardiovascular death, heart attack, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
